CYP7A1 and metabolic dysfunction-associated steatotic liver disease: CYP7A1, a key rate-limiting enzyme in the classic pathway, shows a positive correlation with improvements in NAFLD [27], and free fatty acids have been shown to enhance its hepatic expression [28].